NCT00536770View on ClinicalTrials.gov

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

PHASE2SuspendedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 30, 2007

Conditions
Pancreatic Cancer
Interventions
DRUG

placebo + gemcitabine + erlotinib

DRUG

Placebo + gemcitabine

DRUG

calcitriol + gemcitabine

DRUG

calcitriol + gemcitabine + erlotinib

Trial Locations (1)

Unknown

Novacea Investigational Site, Nashville

Sponsors

Lead Sponsor

Novacea

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

Novacea

INDUSTRY

NCT00536770 - A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter